Related Experiment Video

Updated: Jun 21, 2025

Author Spotlight: Advanced Single-Molecule Techniques for Investigating Telomeric Protein-DNA Interactions
11:21

Author Spotlight: Advanced Single-Molecule Techniques for Investigating Telomeric Protein-DNA Interactions

Published on: August 30, 2024

689

TRF1 and TRF2: pioneering targets in telomere-based cancer therapy

Anoop Kallingal1, Radosław Krzemieniecki2, Natalia Maciejewska2

  • 1Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Gdansk, 80-233, Poland. anoop.kallingal@pg.edu.pl.

Journal of Cancer Research and Clinical Oncology
|July 16, 2024
PubMed

Insights

Telomere Repeat-binding Factors 1 and 2 (TRF1 and TRF2) and the shelterin complex are vital in cancer biology. Their roles as biomarkers and therapeutic targets are crucial for cancer treatment advancements.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Telomere Repeat-binding Factors 1 and 2 (TRF1 and TRF2) are key components of the shelterin complex.
  • The shelterin complex maintains telomere integrity and genomic stability.
  • Dysregulation of TRF1, TRF2, and the shelterin complex is frequently observed in cancer cells.

Purpose of the Study:

  • To explore the roles of TRF1 and TRF2 within the shelterin complex in cancer biology.
  • To highlight their potential as cancer biomarkers and therapeutic targets.
  • To review advancements and challenges in targeting the shelterin complex for cancer therapy.

Main Methods:

  • Literature review synthesizing recent research findings.
  • Analysis of diagnostic and prognostic capabilities of TRF1 and TRF2.
  • Review of drug discovery efforts targeting the shelterin complex.

Main Results:

  • TRF1 and TRF2 are critical for telomere maintenance and genomic stability.
  • TRF1 and TRF2 show diagnostic and prognostic value across various cancer types.
  • Current drug discovery efforts focus on compounds targeting the shelterin complex.

Conclusions:

  • TRF1, TRF2, and the shelterin complex have significant implications in cancer development.
  • Targeting the shelterin complex presents therapeutic opportunities but faces challenges like drug resistance and delivery.
  • Further research is essential to overcome these challenges and harness their full therapeutic potential in oncology.
Keywords:
CancerShelterin complexTRF1TRF2

More Related Videos

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

10.3K
Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells09:13

Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells

Published on: January 17, 2019

7.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded...
23.3K
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K